Industry News (Cachexia)

Patent Allowance Announced for Oxandrin To Treat HIV Wasting

Published in AIDS Weekly, September 6th, 1999

Bio-Technology General Corp., Iselin, New Jersey, announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application with claims to the use of oxandrolone in the treatment of HIV Wasting Syndrome.

This follows the recent issuance to BTG of a U.S. patent with claims directed to the use of oxandrolone in patients suffering from chronic obstructive pulmonary disease.

BTG has been marketing Oxandrin (oxandrolone, USP) in the United States since 1995. Oxandrolone is indicated for the treatment of involuntary weight loss associated with chronic infection, severe trauma, burns, and unknown...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry